Treatment with recombinant FGF21 in diet-induced obese mice and other animal models reduced TG levels and ameliorated hepatic steatosis via inhibiting the lipogenic gene expression (srebp-1), stimulating brown adipose tissue and browning white adipose tissue, and improving insulin resistance [22, 43]. The gene discussed is FGF21; the disease is Insulin resistance.